{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T07:05:54Z","timestamp":1782025554686,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T00:00:00Z","timestamp":1442275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.clinthera.2015.08.003","type":"journal-article","created":{"date-parts":[[2015,9,12]],"date-time":"2015-09-12T08:01:55Z","timestamp":1442044915000},"page":"2366-2380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis"],"prefix":"10.1016","volume":"37","author":[{"given":"Aaron E.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.08.003_bib1","series-title":"Aubagio tablets [US prescribing information]","year":"2014"},{"key":"10.1016\/j.clinthera.2015.08.003_bib2","series-title":"Gilenya (fingolimod) capsules [US prescribing information]","year":"2012"},{"key":"10.1016\/j.clinthera.2015.08.003_bib3","series-title":"Tecfidera capsules [US prescribing information]","year":"2013"},{"key":"10.1016\/j.clinthera.2015.08.003_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1600-0404.2010.01444.x","article-title":"Pathophysiology of multiple sclerosis and the place of teriflunomide","volume":"124","author":"Gold","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.clinthera.2015.08.003_bib5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","article-title":"Teriflunomide and its mechanism of action in multiple sclerosis","volume":"74","author":"Bar-Or","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2015.08.003_bib6","series-title":"Arava tablets [US prescribing information]","year":"2012"},{"key":"10.1016\/j.clinthera.2015.08.003_bib7","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O\u05f3Connor","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clinthera.2015.08.003_bib8","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1212\/01.wnl.0000203121.04509.31","article-title":"A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses","volume":"66","author":"O\u05f3Connor","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2015.08.003_bib9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2015.08.003_bib10","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1474-4422(14)70191-7","article-title":"Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Miller","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2015.08.003_bib11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2015.08.003_bib12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2015.08.003_bib13","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1177\/1352458513475723","article-title":"Magnetic resonance imaging outcomes from a phase III trial of teriflunomide","volume":"19","author":"Wolinsky","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.clinthera.2015.08.003_bib14","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1177\/1352458512450354","article-title":"Pre-specified subgroup analyses of a placebo-controlled Phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis","volume":"18","author":"Miller","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.clinthera.2015.08.003_bib15","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann Neurol"},{"issue":"Suppl 192","key":"10.1016\/j.clinthera.2015.08.003_bib16","first-page":"P458","article-title":"Lack of effect on cardiac repolarisation with teriflunomide compared with placebo: a thorough ECG study","volume":"17","author":"Menguy-Vacheron","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.clinthera.2015.08.003_bib17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/2040622313492810","article-title":"Teriflunomide in relapsing multiple sclerosis: therapeutic utility","volume":"4","author":"Freedman","year":"2013","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.clinthera.2015.08.003_bib18","unstructured":"Miller A, Turpault S, Menguy-Vacheron F. Rapid elimination procedure of teriflunomide with cholestyramine or activated charcoal. Presented at the Fourth Cooperative Meeting of CMSC and ACTRIMS, 30 May\u20132 June 2012, San Diego, CA. P10."},{"key":"10.1016\/j.clinthera.2015.08.003_bib19","first-page":"P849","article-title":"Evaluation of pharmacokinetics and tolerability of oral teriflunomide in subjects with mild and moderate hepatic impairment","volume":"16","author":"Turpault","year":"2010","journal-title":"Mult Scler"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2015.08.003_bib20","first-page":"1","article-title":"Effect of severe renal impairment on the pharmacokinetics and tolerability of teriflunomide","volume":"259","author":"Menguy-Vacheron","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.clinthera.2015.08.003_bib21","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1212\/WNL.0b013e318258f7d4","article-title":"Teriflunomide added to interferon-\u03b2 in relapsing multiple sclerosis: a randomized phase II trial","volume":"78","author":"Freedman","year":"2012","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2015.08.003_bib22","first-page":"P17","article-title":"Oral teriflunomide plus glatiramer acetate in relapsing multiple sclerosis","volume":"13","author":"Freedman","year":"2011","journal-title":"Int J MS Care"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815010097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815010097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T19:35:55Z","timestamp":1711481755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815010097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0149291815010097"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.08.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}